239 related articles for article (PubMed ID: 30207285)
1. A novel algorithm to improve specificity in ovarian cancer detection.
Arjomandi A; Delanoy ML; Walker RP; Binder SR
Cancer Treat Res Commun; 2018; 15():32-35. PubMed ID: 30207285
[TBL] [Abstract][Full Text] [Related]
2. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
Anderson KS; Wong J; Vitonis A; Crum CP; Sluss PM; Labaer J; Cramer D
Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):859-68. PubMed ID: 20200435
[TBL] [Abstract][Full Text] [Related]
3. Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer.
Yang WL; Lu Z; Guo J; Fellman BM; Ning J; Lu KH; Menon U; Kobayashi M; Hanash SM; Celestino J; Skates SJ; Bast RC
Cancer; 2020 Feb; 126(4):725-736. PubMed ID: 31714597
[TBL] [Abstract][Full Text] [Related]
4. Comparison of candidate serologic markers for type I and type II ovarian cancer.
Lu D; Kuhn E; Bristow RE; Giuntoli RL; Kjær SK; Shih IeM; Roden RB
Gynecol Oncol; 2011 Sep; 122(3):560-6. PubMed ID: 21704359
[TBL] [Abstract][Full Text] [Related]
5. Autoantibodies against HSF1 and CCDC155 as Biomarkers of Early-Stage, High-Grade Serous Ovarian Cancer.
Wilson AL; Moffitt LR; Duffield N; Rainczuk A; Jobling TW; Plebanski M; Stephens AN
Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):183-192. PubMed ID: 29141850
[No Abstract] [Full Text] [Related]
6. Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection.
Fortner RT; Damms-Machado A; Kaaks R
Gynecol Oncol; 2017 Nov; 147(2):465-480. PubMed ID: 28800944
[TBL] [Abstract][Full Text] [Related]
7. Tumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation.
Kaaks R; Fortner RT; Hüsing A; Barrdahl M; Hopper M; Johnson T; Tjønneland A; Hansen L; Overvad K; Fournier A; Boutron-Ruault MC; Kvaskoff M; Dossus L; Johansson M; Boeing H; Trichopoulou A; Benetou V; La Vecchia C; Sieri S; Mattiello A; Palli D; Tumino R; Matullo G; Onland-Moret NC; Gram IT; Weiderpass E; Sánchez MJ; Navarro Sanchez C; Duell EJ; Ardanaz E; Larranaga N; Lundin E; Idahl A; Jirström K; Nodin B; Travis RC; Riboli E; Merritt M; Aune D; Terry K; Cramer DW; Anderson KS
Int J Cancer; 2018 Aug; 143(3):515-526. PubMed ID: 29473162
[TBL] [Abstract][Full Text] [Related]
8. Proteomic mapping of p53 immunogenicity in pancreatic, ovarian, and breast cancers.
Katchman BA; Barderas R; Alam R; Chowell D; Field MS; Esserman LJ; Wallstrom G; LaBaer J; Cramer DW; Hollingsworth MA; Anderson KS
Proteomics Clin Appl; 2016 Jul; 10(7):720-31. PubMed ID: 27121307
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53.
Hurley LC; Levin NK; Chatterjee M; Coles J; Muszkat S; Howarth Z; Dyson G; Tainsky MA
Cancer Biomark; 2020; 27(3):407-421. PubMed ID: 32083570
[TBL] [Abstract][Full Text] [Related]
10. p53-autoantibody may be more sensitive than CA-125 in monitoring microscopic and macroscopic residual disease after primary therapy for epithelial ovarian cancer.
Häfner N; Nicolaus K; Weiss S; Frey M; Diebolder H; Rengsberger M; Dürst M; Runnebaum IB
J Cancer Res Clin Oncol; 2013 Jul; 139(7):1207-10. PubMed ID: 23576021
[TBL] [Abstract][Full Text] [Related]
11. P53 autoantibodies in sera from Danish ovarian cancer patients and their correlation with clinical data and prognosis.
Høgdall EV; Høgdall CK; Blaakaer J; Heegaard NH; Glud E; Christensen L; Bock JE; Nørgaard-Pedersen B; Wiik A; Kjaer SK
APMIS; 2002 Aug; 110(7-8):545-53. PubMed ID: 12390412
[TBL] [Abstract][Full Text] [Related]
12. [Clinical study of autoantibody spectrum against ovarian cancer associated antigens combined with CA(125) in detecting and monitoring ovarian cancer].
Yang ZJ; Yang G; Jiang YM; Ran YL; Yang ZH; Zhang W; Zhang JQ; Pan ZM; Li L
Zhonghua Fu Chan Ke Za Zhi; 2011 Feb; 46(2):113-8. PubMed ID: 21426769
[TBL] [Abstract][Full Text] [Related]
13. Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer.
Yang WL; Gentry-Maharaj A; Simmons A; Ryan A; Fourkala EO; Lu Z; Baggerly KA; Zhao Y; Lu KH; Bowtell D; Jacobs I; Skates SJ; He WW; Menon U; Bast RC;
Clin Cancer Res; 2017 Oct; 23(19):5912-5922. PubMed ID: 28637689
[No Abstract] [Full Text] [Related]
14. p53 autoantibodies, cytokine levels and ovarian carcinogenesis.
Tsai-Turton M; Santillan A; Lu D; Bristow RE; Chan KC; Shih IeM; Roden RB
Gynecol Oncol; 2009 Jul; 114(1):12-7. PubMed ID: 19398128
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Role of Serum Antibody Immunity to p53 Oncogenic Protein in Ovarian Cancer: A Systematic Review and a Meta-Analysis.
Garziera M; Montico M; Bidoli E; Scalone S; Sorio R; Giorda G; Lucia E; Toffoli G
PLoS One; 2015; 10(10):e0140351. PubMed ID: 26451959
[TBL] [Abstract][Full Text] [Related]
16. Autoantibody signature for the serologic detection of ovarian cancer.
Anderson KS; Cramer DW; Sibani S; Wallstrom G; Wong J; Park J; Qiu J; Vitonis A; LaBaer J
J Proteome Res; 2015 Jan; 14(1):578-86. PubMed ID: 25365139
[TBL] [Abstract][Full Text] [Related]
17. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of colorectal cancer.
Fan CW; Kuo YB; Lin GP; Chen SM; Chang SH; Li BA; Chan EC
Clin Chim Acta; 2017 Dec; 475():157-163. PubMed ID: 29074220
[TBL] [Abstract][Full Text] [Related]
18. Using protein microarray to identify and evaluate autoantibodies to tumor-associated antigens in ovarian cancer.
Ma Y; Wang X; Qiu C; Qin J; Wang K; Sun G; Jiang D; Li J; Wang L; Shi J; Wang P; Ye H; Dai L; Jiang BH; Zhang J
Cancer Sci; 2021 Feb; 112(2):537-549. PubMed ID: 33185955
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of serum autoantibodies against tumor-associated antigens as biomarkers in lung cancer.
Li P; Shi JX; Xing MT; Dai LP; Li JT; Zhang JY
Tumour Biol; 2017 Oct; 39(10):1010428317711662. PubMed ID: 29022480
[TBL] [Abstract][Full Text] [Related]
20. Ultrasensitive bioassay of epitope of Mucin-16 protein (CA 125) in human plasma samples using a novel immunoassay based on silver conductive nano-ink: A new platform in early stage diagnosis of ovarian cancer and efficient management.
Jafari M; Hasanzadeh M; Solhi E; Hassanpour S; Shadjou N; Mokhtarzadeh A; Jouyban A; Mahboob S
Int J Biol Macromol; 2019 Apr; 126():1255-1265. PubMed ID: 30615961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
